SCHEMBL31396179

SCHEMBL31396179

CC(C)(C)OC(=O)N1CCN(c2cc(F)cc(Br)n2)CC12CC2

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 5/20 0.41
▸ JAK3 P52333 2/20 0.39
▸ NR1H2 P55055 1/20 0.34
▸ NR1H3 Q13133 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ PIK3CA P42336 1/20 0.33
▸ F2RL1 P55085 2/20 0.33
▸ GPR119 Q8TDV5 2/20 0.32
▸ CYP11B2 P19099 1/20 0.32
▸ CKS1B P61024 1/20 0.32
▸ SKP1 P63208 1/20 0.32
▸ SKP2 Q13309 1/20 0.32
▸ TRPC6 Q9Y210 1/20 0.32
▸ NTRK1 P04629 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC2 Q92769 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31396262 0.84 ALDH1A1 (0.42) RETJAK3NR1H2NR1H3KCNH2
SCHEMBL31401286 0.82 RET (0.47) RETJAK3NR1H2NR1H3GPR119
SCHEMBL31383499 0.81 CKS1B (0.48) RETKCNH2GPR119CKS1BSKP1
SCHEMBL31267843 0.79 RET (0.45) RETJAK3NR1H2NR1H3GPR119
SCHEMBL31713549 0.78 RET (0.52) RETJAK3GPR119TRPC6NTRK1
SCHEMBL30270990 0.78 RET (0.41) RETJAK3NR1H2NR1H3
SCHEMBL31396207 0.77 RET (0.41) RETJAK3NR1H2NR1H3GPR119
SCHEMBL31713817 0.77 GPR119 (0.44) RETJAK3GPR119TRPC6
SCHEMBL16540062 0.76 JAK3 (0.43) RETJAK3NR1H2NR1H3GPR119
SCHEMBL31401450 0.76 RET (0.46) RETJAK3NR1H2NR1H3GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739684-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
WO-2025008060-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
Send feedback